Biomerica (NASDAQ:BMRA) Issues Quarterly Earnings Results, Beats Estimates By $0.76 EPS

Posted by Lauren Steadman on Apr 14th, 2026

Biomerica (NASDAQ:BMRA – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.76, Zacks reports. Biomerica had a negative return on equity of 83.73% and a negative net margin of 90.29%.The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $3.63 million.

Biomerica Trading Down 2.3%

NASDAQ:BMRA opened at $2.08 on Tuesday. Biomerica has a 12-month low of $1.87 and a 12-month high of $4.88. The stock’s 50 day simple moving average is $2.14 and its 200-day simple moving average is $2.44. The firm has a market cap of $6.28 million, a P/E ratio of -2.24 and a beta of 0.20.

Hedge Funds Weigh In On Biomerica

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC grew its position in shares of Biomerica, Inc. (NASDAQ:BMRA – Free Report) by 62.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the quarter. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 as of its most recent filing with the SEC. Institutional investors own 22.28% of the company’s stock.

About Biomerica

(Get Free Report)

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.